E
Ergomed
Specialized services to the pharmaceutical industry and the development of new drugs
About Ergomed
Ergomed plc is a global Contract Research Organization (CRO) with over 23 years of experience, providing specialized services to the pharmaceutical industry. The company supports the development of new drugs from proof of concept to late-stage programs, ensuring the highest standards in clinical trials. Ergomed serves over 100 clients worldwide, including pharmaceutical and biotechnology companies, focusing on complex and challenging studies. The business operates in the pharmaceutical development market, leveraging a co-development business model to support product development, particularly in the European region. Ergomed generates revenue through service contracts with its clients, offering tailored solutions for each stage of drug development. The company has successfully transitioned to remote operations with minimal disruption, demonstrating resilience and adaptability in the face of challenges like the COVID-19 pandemic.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1997
- Headquarters
- Guildford, United Kingdom
- Listing
- IPO 2014
- Employees
- 716
- Open positions
- None listed
- Dealroom signal
- 73.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, uk is8 life sciences
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 6 companies, latest Jan 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Sep 2025 | $10M | — | Undisclosed | ↗ |
| ACQUISITION✓Exit | Sep 2023 | $928M | $928M | Permira | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ergomed is 140 monthly website visits, down 97% over the last three months. Ergomed's team grew 2.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PHV LatamArgentinaProduct lifecycle safety solutions for Latin America
→
MedSourceHouston, United StatesAn award-winning clinical research organization (CRO) that delivers high-quality clinical trials through strong relationships and specializes in oncology, neurology/CNS, and infectious diseases
$16Mvaluation
Ashfield HealthcareAshby de la Zouch, United KingdomOutsourced healthcare services to pharmaceutical, device and biotech companies
$10Mvaluation
PSR Orphan ExpertsHoofddorp, NetherlandsPSR Group, an international niche contract research organisation
$6.3Mvaluation
HaemostatixNottingham, United KingdomPeptide-based coagulants for controlling surgical bleeding
$325Kvaluation
PrimeVigilanceGuildford, United KingdomPrimeVigilance Ltd, operates as a pharmacovigilance and medical information services company
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Catapult Ventures
Other known investors1 additional known investor
Permira
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ergomed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ergomed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.